Radiopharm Theranostics enters the back half of calendar 2026 as a dual-listed Australian radiopharmaceutical developer that has finally produced a clean imaging readout and still cannot fund the next step from cash on hand. The Phase IIb study of RAD101, a fluorine-labeled small molecule aimed at fatty acid synthase in suspected recurrent brain metastases, met its primary endpoint with high concordance against magnetic resonance imaging. That result is the first piece of evidence that the company's most advanced asset can do something commercially recognizable: help physicians tell active brain metastases from treatment effect, a distinction standard MRI often cannot make. The same fiscal year that delivered the readout also emptied the treasury and put a going-concern paragraph on the calendar for the audited accounts due at month-end.
The tension is not scientific ambiguity. It is whether a micro-cap that closed June with A$4 million of cash can carry six live trials, a Siemens Healthineers supply pact, and a planned registrational study without another round of deeply discounted equity. Operating cash outflow in the June quarter alone ran near A$15 million. After year-end the company collected a multi-million Australian research-tax rebate, completed a discounted institutional placement, and ran a share purchase plan. Those inflows extend the clock. They do not change the fact that last year's burn consumed more than the entire year-end cash pile several times over. The American depositary share now trades near the bottom of its fifty-two-week range, which is the market's verdict on that math.
The next few months resolve a narrow question. An end-of-Phase-two meeting with the Food and Drug Administration is scheduled for early October, and management is positioning the program to be Phase III ready by year-end. If the agency aligns on a workable registrational design and Siemens can actually put doses into American sites, RAD101 becomes a financeable imaging asset rather than a headline milestone. If the meeting produces a larger trial, extra endpoints, or a request for more follow-up, the cash gap reopens immediately. Therapeutic programs remain real but still early: a confirmed partial response in the PD-L1 nanobody RAD204, dose escalation in the HER2 nanobody RAD202, and the MD Anderson B7-H3 antibody. They cannot carry the equity if the imaging path stalls.